HLB Therapeutics Co.,Ltd.

115450KOSDAQWholesale and commodity brokerage

HLB Therapeutics Co.,Ltd. (115450, KOSDAQ) reported KRW 70bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
202354-9-3201172Consolidated
202455-8-23220182Consolidated
202570-4-10229174Consolidated

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
2023-16.2%-5.7%85.4%-1.8%
2024-13.9%-42.7%82.7%-12.9%
2025-5.1%-13.9%76%-5.6%

Revenue moved 29.4% between 2023 and 2025.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 177bn
Close priceKRW 1,999
Listed shares88,580,109
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

Workforce — a side measure, not the main one

Employees (2025)50
Women14 (28%)
Average tenure2.7 years
Annual pay, menKRW 52,981,861
Annual pay, womenKRW 37,486,429
Pay ratio, women to men70.8%

Other companies in Wholesale and commodity brokerage

117 listed companies file under this classification. Showing 12.

See the whole Wholesale and commodity brokerage list →